Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 4/20 | 0.45 |
| ▸ | NOS1 | P29475 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522979 | 0.94 | NOS3 (0.50) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL6871648 | 0.93 | NOS3 (0.49) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL6871642 | 0.92 | NOS3 (0.48) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL5033332 | 0.86 | MAOB (0.52) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL5519147 | 0.84 | MAOB (0.50) | MAOBMAOAMAPTNOS3NOS1 | |
| SCHEMBL5033238 | 0.84 | MAPT (0.54) | MAOBCYP3A4MAOAMAPTNOS3 | |
| SCHEMBL5513403 | 0.81 | MAPT (0.45) | MAOBCYP3A4MAPTTSHRRECQL | |
| SCHEMBL5036075 | 0.80 | MAOB (0.47) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL5035944 | 0.79 | HRH3 (0.48) | MAOBCYP3A4MAOAMAPTTSHR | |
| SCHEMBL5037525 | 0.79 | HRH3 (0.48) | MAOBCYP3A4MAOAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100376557-C | Quinoline derivatives as ligands for neuropeptide Y receptors | HOFFMANN LA ROCHE (CH) | 2008-03-26 | — | — | CN | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| CN-1522249-A | Quinoline derivatives as ligands for neuropeptide Y receptors | — | 2004-08-18 | — | — | CN | disclosed |
| EP-1395564-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002094789-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAOB 1279/4885CYP3A4 3415/4885MAOA 1633/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAOB 1279/4885CYP3A4 3415/4885MAOA 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.